Precision m⁶A Site Mapping – Uncover the Epitranscriptome Blueprint of Your RNA

If you are searching for N6‑methyladenosine (m⁶A) site determination, you are likely seeking to identify exactly where this reversible RNA modification occurs on your transcripts of interest – or across the entire transcriptome. m⁶A regulates RNA stability, splicing, translation, and decay, but detecting individual modification sites with confidence requires specialized biochemical and bioinformatic methods. Our service provides single‑nucleotide resolution mapping of m⁶A sites in any RNA sample, from total RNA to enriched coding and non‑coding transcripts. We deliver not just a list of peaks, but validated, position‑specific methylation calls backed by orthogonal evidence.

What We Determine and at What Resolution

We go far beyond standard MeRIP‑seq or m⁶A‑seq, which typically achieve ~100‑200 nt resolution. Our integrated pipeline combines three orthogonal technologies to pinpoint m⁶A at base resolution:

1. m⁶A cross‑linking and immunoprecipitation (miCLIP) – using a mutated m⁶A antibody (E. coli) that creates cross‑linking‑induced truncations or mutations at modified adenosines. We achieve single‑nucleotide accuracy with a false discovery rate below 1% after our stringent bioinformatic filtering.
2. MAZTER‑seq / m⁶A‑REF‑seq – orthogonal RNase H‑based cleavage that distinguishes m⁶A from unmodified A at specific sequence contexts (e.g., AAC, GAC).
3. Direct RNA sequencing (Oxford Nanopore) – we train custom neural network models (m6Anet + our proprietary modification caller) to detect m⁶A in native RNA molecules without antibody bias, achieving 94‑97% precision at single‑site resolution for DRACH motifs and beyond.

For each sample, we deliver a base‑resolution m⁶A annotation table with modification stoichiometry (percentage methylation at each site), motif context, and cross‑platform confidence scores. We can detect sites with as low as 5% methylation frequency in a mixed cell population.

Scope of Detectable m⁶A Sites and Sample Types

The table below summarizes the range of m⁶A detection parameters we routinely handle.

We also provide differential m⁶A analysis between two or more conditions (e.g., control vs drug treatment, wild‑type vs METTL3 knockout), identifying sites with statistically significant changes in modification fraction (adjusted p‑value <0.05).

Our Unmatched Advantages in m⁶A Site Determination

Accurately calling m⁶A positions is technically challenging – many commercial services provide only low‑resolution peak lists or fail on low‑input samples. Our service differentiates itself through the following:

1. Multi‑platform validation – Every candidate m⁶A site reported from miCLIP or Nanopore is cross‑checked with at least one orthogonal method (MAZTER‑seq or site‑specific m⁶A‑qPCR). This eliminates false positives caused by antibody cross‑reactivity or basecalling errors. We publish our validation success rate: >90% of high‑confidence sites confirmed.

2. Advanced bioinformatics pipeline – We developed m6A‑caller v3.0 that integrates signal from all three platforms using a Bayesian hidden Markov model. The pipeline corrects for sequence context biases, RNA structure, and library preparation artifacts. We provide a confidence score (0‑1) for each nucleotide, enabling you to prioritize sites for functional studies.

3. Single‑cell m⁶A determination (optional) – For rare or heterogeneous populations, we offer scm6A‑seq (single‑cell m⁶A sequencing) based on split‑pool barcoding, detecting modification sites in 200‑500 individual cells per run. This reveals cell‑to‑cell variability in epitranscriptomic regulation.

4. Low input and clinical samples – Our proprietary m6A‑LITE protocol adapts miCLIP for as little as 10 ng of total RNA (e.g., from laser‑capture microdissection or liquid biopsy exosomes). We have successfully processed FFPE‑derived RNA with DV200 as low as 30%.

5. Rapid turnaround and flexible scale – Standard miCLIP + Nanopore analysis for 8 samples takes 3 weeks. For smaller projects (1‑4 samples), we offer an expedited 10‑day service. High‑throughput projects (96+ samples) are processed in 5 weeks with robotic automation.

6. Functional interpretation – Beyond site detection, we integrate m6A motif enrichment, predicted reader protein binding (YTHDF1/2/3, YTHDC1, IGF2BP1‑3), and effect on RNA secondary structure using our in‑house database of >150,000 validated m⁶A sites from 30+ cell types. Each report includes a table linking identified sites to potential biological consequences (e.g., altered splicing events, miRNA binding changes).

7. Transparent quality control – We include spike‑in controls (synthetic RNAs with known methylation status at defined positions) in every run to calculate sensitivity and specificity. You receive a full QC report showing replicate concordance, cross‑platform overlap, and false discovery estimates.

8. No‑risk pilot option – If you are unsure about your RNA quality or the presence of m⁶A in your samples, we offer a pilot assay on up to 3 samples at half price, with results delivered in 14 days. If the pilot fails to yield reliable sites, you pay only for consumables.

Ready to Map Your m⁶A Epitranscriptome?

Whether you need to validate a single suspected m⁶A site in one gene, or build a whole‑transcriptome atlas under five different conditions, our N6‑methyladenosine site determination service provides the accuracy, depth, and validation you require. Start by submitting your sample list through our online portal; we will recommend the optimal assay (miCLIP, Nanopore, or combination) based on your RNA quantity, species, and research question. Free 30‑minute consultation with our epitranscriptomics specialist included. Email rna@m6asite.com or call +1 (650) 555‑M6A1 to discuss your project. No fixed logic – just precise, validated m⁶A positions you can trust for publication and follow‑up mechanism studies.